Sera Prognostics Q3 2026 Earnings: Test Growth Outpaces Monetization

Sera Prognostics (NASDAQ: SERA) reported fiscal Q3 2026 revenue of $42,000, up 163% from $16,000 a year earlier, while GAAP diluted EPS was -$0.16, unchanged year over year. PreTRM test volume increased 54% sequentially, but a higher mix of low- or non-reimbursed tests reduced average selling prices and limited revenue conversion. The company recorded an $8.1 million net loss, used $7.3 million of cash in operations during the quarter and ended September with $72.8 million in cash and investments.

Core Financial Results

Revenue growth came from increased PreTRM testing activity, but revenue remained below the $61,000 cost of revenue. That resulted in an approximate gross loss of $19,000, compared with an approximate $25,000 gross loss in the prior-year quarter.

Operating expenses were nearly flat year over year, and the operating loss narrowed slightly. However, other income declined to $836,000 from $1.2 million, contributing to a modestly wider net loss.

All figures in the table are GAAP and unaudited. Gross loss is calculated as revenue less reported cost of revenue.

PreTRM Adoption and Reimbursement Progress

PreTRM test volume increased 54% from Q2 and was almost five times the Q1 2026 level. The number of ordering healthcare providers rose 34% sequentially and was approximately three times the Q1 level, although Sera did not disclose absolute test or provider counts.

Florida became the second state to establish Medicaid coverage for PreTRM after adding the test’s PLA code, 0247U, to its covered biomarker list and laboratory fee schedule. Florida has approximately 4 million Medicaid beneficiaries and 90,000 Medicaid births annually, bringing Sera’s total covered Medicaid population to about 7 million people.

In Illinois, the same code was placed on the Medicaid fee schedule at $525 without a prior-authorization requirement. Sera has completed state credentialing and is working to secure contracts with Medicaid managed-care plans.

The company also launched its fourth payer partnership program and is discussing a multi-state, multi-thousand-patient pilot with a large commercial insurer for fiscal 2027. These discussions have not yet been presented as a finalized contract or quantified revenue opportunity.

Outside the United States, Sera began the CE Mark submission process for the kit-based PreTRM Global test. The European Association of Perinatal Medicine also referenced PreTRM as a potential preterm-birth risk prediction tool. Separately, a PRIME trial subgroup analysis found that PreTRM-guided care reduced NICU admissions among first-time mothers by 22%.

Profitability, Cash Flow and Liquidity

Total operating expenses declined 11% sequentially following cost reductions implemented in June 2026. The savings were partly offset by increased commercial spending for the Illinois and Florida launches and approximately $0.4 million of restructuring-related severance expense.

The expense mix shows Sera shifting resources toward commercialization. Selling and marketing expense increased approximately 41% year over year to $2.3 million, while research and development expense declined approximately 17% to $2.7 million. General and administrative expense decreased approximately 5% to $3.9 million.

Sera used $7.3 million of cash in operations during Q3. For the nine months ended September 30, operating cash outflow was $22.4 million, compared with $19.5 million in the prior-year period. This nine-month comparison should not be confused with the quarterly cash-burn figure.

At quarter-end, cash and cash equivalents totaled $4.0 million, while current and long-term marketable securities totaled $68.8 million. Combined cash, cash equivalents and marketable securities were $72.8 million.

Adoption Is Rising Faster Than Monetization

The central issue in the quarter was the gap between operating adoption and recognized revenue. Test volume and ordering-provider counts rose sharply, but quarterly revenue was only $42,000 because more tests were either reimbursed at low rates or not reimbursed at all. Revenue also remained below direct cost of revenue.

Florida and Illinois Medicaid coverage expand the pool of patients for whom reimbursement may be available, but coverage does not immediately translate into collected revenue. Sera still needs to complete managed-care contracting, increase physician ordering and improve the mix of reimbursed tests. At the same time, it is expanding its sales organization, which increased by 25% during Q3 and grew again in October to support Florida commercialization.

This creates a timing mismatch: commercial costs are rising now, while broader reimbursement and revenue conversion remain in development. The pace at which covered testing turns into paid testing is therefore more informative than test-volume growth alone.

Recent Insider Transactions

The supplied insider data categorized 348,832 shares as purchases and 83,723 shares as sales over the latest six-month period, resulting in net purchases of 265,109 shares. The ten most recent reported transactions consisted of six sales and four stock awards; all were classified as direct transactions.

The six reported sales had an aggregate value of approximately $79,563. Stock awards should not be interpreted as open-market purchases, and the transaction data alone does not establish insiders’ views about the company’s prospects.

Risks for Investors to Watch

• Reimbursement remains the main monetization constraint. A high proportion of low- or non-reimbursed tests reduced average selling prices even as volume increased.
• Losses and cash consumption remain substantial relative to revenue. Sera generated $42,000 of quarterly revenue but recorded an $8.1 million net loss and $7.3 million of quarterly operating cash burn.
• Commercial spending may precede revenue conversion. Sales and marketing expense increased as Sera expanded its sales organization and prepared Medicaid launches in Illinois and Florida.
• PreTRM concentration increases execution risk. The test represents substantially all company revenue to date, making broader clinical adoption, payer coverage and reimbursement central to financial progress.
• Coverage does not guarantee payment volume. Managed-care contracting in Illinois remains underway, while the proposed commercial-insurer pilot was still under discussion.

Summary

Sera Prognostics made measurable progress in PreTRM adoption during Q3 2026, supported by higher test volume, more ordering providers and expanded Medicaid coverage. The financial benefit remains limited because reimbursement mix pressured average selling prices, leaving revenue below direct cost and losses substantial. The next important measure of execution is whether Florida and Illinois coverage, commercial-payer programs and a larger sales organization can convert growing clinical use into paid testing without accelerating cash consumption.